Welcome to our dedicated page for JIN MED INTL LTD. news (Ticker: ZJYL), a resource for investors and traders seeking the latest updates and insights on JIN MED INTL LTD. stock.
Jin Medical International Ltd. (Nasdaq: ZJYL) is a Cayman Islands holding company with Chinese operating entities that manufacture wheelchairs, rehabilitation medical equipment and living aids products. This news page aggregates announcements, press releases and updates related to Jin Medical’s operations, product lines, collaborations and capital markets activity.
Company news often covers developments in its rehabilitation equipment and assistive technology portfolio, including manual and electric wheelchairs, nano-thermal bath equipment, micro-hyperbaric oxygen chambers and lifestyle beauty and health devices. Updates have highlighted expansion of manufacturing capacity, such as the construction and launch of production at the intelligent manufacturing facility in Chuzhou, Anhui Province, as well as the operation of existing plants in Changzhou and Taizhou in Jiangsu Province.
Jin Medical’s releases also describe strategic projects and partnerships, including orders for micro-hyperbaric oxygen chambers, cooperation on lifestyle beauty equipment, participation in elderly care initiatives like the "Lao Le Hui" Assisted Bathing Project, and potential acquisitions in the medical equipment sharing field. Capital markets and regulatory items, such as Nasdaq listing notifications and financial result announcements, are reported through SEC filings and accompanying press communications.
Investors, analysts and observers can use this news feed to follow how Jin Medical’s rehabilitation and health-related products are being deployed, how its manufacturing footprint evolves, and how management communicates about listing compliance, governance changes and financial performance. Regularly reviewing these updates provides context on the company’s activities within the surgical and medical instrument manufacturing sector and its role in assistive technologies and health-focused equipment.
Jin Medical (NASDAQ:ZJYL) hosted a CEO Fireside Chat on February 2, 2026 outlining strategic priorities and operational plans. Key points: board-authorized reverse split proposal, 2026–2027 focus on commercialization after product certifications, manufacturing scale-up, cost normalization, and regional/international expansion.
The company said its Chuzhou factory is expected to reach full capacity by end of April 2026 and will support automation, lower unit costs, and tighter quality control as part of disciplined capital allocation.
Jin Medical International (NASDAQ: ZJYL) will host a management fireside chat on Feb 1, 2026 at 8:00 PM EST, led by the CEO and the management team. The discussion will cover the company's recent strategic priorities and long-term growth considerations. The event will be webcast on the company's updated corporate website at http://www.jinmed.com. Investors can view the live webcast on the site for direct comments from management and insight into the company’s strategic direction.
Jin Medical (NASDAQ: ZJYL) announced its Chuzhou, Anhui manufacturing facility achieved final construction milestones and regulatory clearance for Class I medical device production on Dec 29, 2025. The company projects to begin full-capacity production by the end of April 2026, with an annual capacity of 200,000 units of mid-to-high-end electric wheelchairs and senior mobility scooters.
Located in the Yangtze River Delta, the facility will use automated lines to improve cost control, product quality, and supply-chain resilience, supporting domestic and international demand for assistive devices.
Jin Medical International (NASDAQ: ZJYL) said members of its management team will host a fireside chat on February 1, 2026 to discuss the company’s strategic priorities and capital structure considerations.
The session will cover recent market developments, the framework of ongoing strategic planning, and management’s decision-making approach. Management stated it believes the company has a strong liquidity position and is evaluating a range of strategic options to enhance competitive positioning.
Jin Medical International (NASDAQ:ZJYL) has launched production at Plant No. 3 of its intelligent manufacturing facility in Chuzhou, Anhui, China. The state-of-the-art facility features robotic arms and temperature-controlled workshops with an annual production capacity of 200,000 units.
The company, leveraging 19 years of rehabilitation technology expertise, manufactures various products including ultra-light wheelchairs, Paralympic-certified competition equipment, micro hyperbaric oxygen chambers, and beauty devices. The facility meets Japanese Industrial Standards (JIS) certification requirements and is preparing to supply electric wheelchairs to markets in Istanbul, Jerusalem, and Tokyo.
Jin Medical International (NASDAQ: ZJYL) has received a deficiency notice from Nasdaq on May 2, 2025, due to non-compliance with the minimum bid price requirement. The company's stock price remained below $1.00 for 30 consecutive business days between March 20 and May 1, 2025. ZJYL has been granted a 180-day compliance period until October 29, 2025, to regain compliance by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive business days.
If unsuccessful, the company may be eligible for an additional 180-day period, provided it meets other Nasdaq Capital Market listing requirements. Options for compliance include implementing a reverse stock split. Failure to meet requirements could result in delisting from Nasdaq.
JIN MEDICAL INTERNATIONAL (NASDAQ: ZJYL), a leader in Assistive Technologies (AT) and manufacturer of wheelchairs and living aids, has announced the start of construction for its new manufacturing facility in Chuzhou City, Anhui Province, China. The facility, operated by JinMed (Anhui) Co., , will be an internationally standardized, innovative, and high-end wheelchair manufacturing plant.
The new facility is expected to strengthen JinMed's position in the AT industry with higher-level production lines and more innovative products. Targeted to operate in 2025, it will expand capacity for manual wheelchairs and introduce production lines for electric wheelchairs, electric scooters, micro hyperbaric chambers, and scientific cosmetic products.
CEO Wang Erqi stated that this development marks a major milestone for JinMed, aligning with their goal of 'global technology for the benefit of mankind' and demonstrating the company's commitment to industry leadership.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of JIN MED INTL LTD. (ZJYL)?
What is the market cap of JIN MED INTL LTD. (ZJYL)?
